Related Experiment Videos
[Gastrointestinal peptides among new therapeutic agents used in type 2 diabetes]
S Efendic1, T Bystedt, C G Ostenson
1Kliniken för endokrinologi och diabetologi, Karolinska sjukhuset, Stockholm.
Lakartidningen
|March 25, 1999
Abstract:
The pharmacological arsenal available today for the treatment of type II diabetes is often insufficient to allow optimal control of the disease. Each agent corrects only one or a few of the multiple defects that characterise type II diabetes. Currently, new drugs are under development that target several of the clinical abnormalities. These agents include the gastrointestinal peptides, glucagon-like polypeptide-1 (GLP-1) and amylin, and their analogues. New rapid- and long-acting insulin analogues will also constitute interesting treatment alternatives.